Can lorazepam and Belsomra (suvorexant) be safely co‑prescribed?

Can Lorazepam and Belsomra Be Safely Co-Prescribed?

Lorazepam and Belsomra (suvorexant) can be co-prescribed together, but this combination requires mandatory dose reduction of one or both agents due to additive CNS depression, and patients must be explicitly warned about significantly increased risks of next-day impairment, falls, and complex sleep behaviors.

Key Safety Considerations from FDA Labeling

The FDA label for Belsomra explicitly addresses benzodiazepine co-administration 1:

• Co-administration with benzodiazepines increases the risk of CNS depression
• Dosage adjustments of BELSOMRA and/or the benzodiazepine are necessary when administered together due to potentially additive effects
• The combination increases risk of:
  • Next-day somnolence and driving impairment
  • Falls (particularly in elderly patients)
  • Complex sleep behaviors (sleep-walking, sleep-driving)
  • Prolonged CNS depressant effects lasting several days

Practical Dosing Algorithm When Combining

When you must use both medications together 1:

1. Start with lower Belsomra dose: Use 5 mg (not the standard 10 mg starting dose)
2. Reduce lorazepam dose: Consider cutting the benzodiazepine dose by 25-50%
3. Maximum Belsomra dose: Generally should not exceed 10 mg when combined with benzodiazepines
4. Monitor closely: Assess for excessive sedation, falls risk, and next-day impairment

Patient-Specific Risk Factors Requiring Extra Caution

The combination is particularly hazardous in 1:

• Obese women: Suvorexant exposure increased by 46% (AUC) and 25% (Cmax) compared to non-obese females
• Elderly patients: Higher fall risk due to drowsiness
• Patients taking CYP3A4 inhibitors: Further increases suvorexant levels
• Patients who drive: Formal driving studies showed impairment at 20 mg dose

Clinical Context: Why This Matters

The FDA warnings are not theoretical 1. The label states that "co-administration with other CNS depressants (e.g., benzodiazepines, opioids, tricyclic antidepressants, alcohol) increases the risk of CNS depression" and explicitly requires dosage adjustments. One case report demonstrated next-day somnolence even with a moderate CYP3A4 inhibitor (diltiazem) in an elderly patient 2, illustrating how drug interactions compound CNS depression risk.

Alternative Strategy to Consider

The FDA label explicitly states: "The use of BELSOMRA with other drugs to treat insomnia is not recommended" 1. This suggests the preferred approach is:

• Transition rather than combine: Switch from lorazepam to suvorexant rather than using both simultaneously
• Evidence supports this: A 2022 study showed successful switching from benzodiazepines to suvorexant in patients with major depressive disorder and insomnia, with improved insomnia severity scores and good tolerability 3

Mandatory Patient Warnings

If you proceed with combination therapy, patients must be counseled 1:

• Do not consume alcohol with this combination
• Avoid driving the next day, especially initially
• Take only with ≥7 hours remaining before needing to be alert
• Report immediately: Any episodes of sleep-walking, sleep-driving, or activities performed while not fully awake
• Fall precautions: Particularly for elderly patients getting up at night

Bottom Line

While not absolutely contraindicated, combining lorazepam with Belsomra requires dose reduction of one or both agents per FDA labeling, heightened monitoring for CNS depression, and explicit patient counseling about increased risks. The preferred strategy is transitioning from the benzodiazepine to suvorexant rather than chronic combination therapy, as the FDA specifically recommends against using Belsomra with other insomnia medications 1.